


**Caixalmpulse** *Health Innovation Call 2025* 

# Innovation form



caixaresearch.org



## Introduction

As explained in the Rules of Participation, Project Leaders may submit their Project to Stage 1, 2 or 3 of the Programme. To complete the application, candidates should fill in the block 0, which is common to the three stages of the programme. Within this block 0, applicants will find a guideline to help them choose the Stage of the Programme their project fits best. In the question "Please, choose the scenario that better matches the current status of your project" they should select Scenario 1, if they wish to apply for Stage 1; Scenario 2 to apply for Stage 2, and Scenario 3 to apply for Stage 3. After this selection, a different form will appear depending upon the selected Stage.

# Common to all stages

Block 0 – General data and proposal information

## **APPLICATION DETAILS**

- » Call name:
- » Application number:
- » Proposal Title: 100 characters, mandatory.
- » Proposal Description: 200 characters, mandatory.
- » Proposal Acronym: 20 characters, mandatory.
- » Project Leader:
- » Host Organization:
- » Faculty or Research Center (if applicable): 100 characters, optional.
- » Is the Project Leader the principal investigator of the research group developing the Asset? Yes/No. Mandatory.


## If user answers No to the previous question:

Please identify the research group developing the Asset/s in the Host Organization (i.e., by means of the Principal Investigator in charge and, if possible, the lab name): **100 characters, mandatory.** 

In collaboration with:

Criteria*Bio*Ventures <u>X Caixa Capital Risc</u>





## **CLASSIFICATION OF THE APPLICATION**

If \* is shown, the answers to that question are locked from modification when changing status from Pre-draft to Draft. User must return to Pre-draft status to modify these fields.

## Select the business area of your project, mandatory.

	Therapeutics	
	Diagnostics	
	Medical Devices	
	Digital Health	

## Select the scientific area(s) of your project, mandatory.

Molecular and Structural Biology and Biochemistry
Genetics, Genomics, Bioinformatics and Systems Biology
Cellular and Developmental Biology
Physiology, Pathophysiology and Endocrinology
Neurosciences and Neural Disorders
Immunity and Infection
Diagnostic Tools, Therapies and Public Health
Applied life Sciences and Non-Medical Biotechnology


## Select the relevant subareas of your project, it is mandatory to select between 2 and 4.

1Molecular and Structural Biology and Biochemistry1Molecular interactions	
1_2 General biochemistry and metabolism	
1_3 DNA synthesis, modification, repair, recombination and degradation	
1_4 RNA synthesis, processing, modification and degradation	
1_5 Protein synthesis, modification and turnover	
1_6 Lipid synthesis, modification and turnover	
1_7 Carbohydrate synthesis, modification and turnover	
<b>1_8</b> Biophysics (e.g. transport mechanisms, bioenergetics, fluorescence)	
1_9 Structural biology (crystallography and EM)	
1_10 Structural biology (NMR)	
1_11 Biochemistry and molecular mechanisms of signal transduction	
2 Genetics, Genomics, Bioinformatics and Systems Biology	
2_1 Genomics, comparative genomics, functional genomics	
2_2 Transcriptomics	
2_3 Proteomics	
2_4 Metabolomics	
2_5 Glycomics	
2_6 Molecular genetics, reverse genetics and RNAi	
2_7 Quantitative genetics	
2_8 Epigenetics and gene regulation	
2_9 Genetic epidemiology	
2_10 Bioinformatics	
2_11 Computational biology	
2_12 Biostatistics	
2_13 Systems biology	
2_14 Biological systems analysis, modelling and simulation	

In collaboration with:







3	Cellular and Developmental Biology
3_1	Morphology and functional imaging of cells
3_2	Cell biology and molecular transport mechanisms
3_3	Cell cycle and division
3_4	Apoptosis
3_5	Cell differentiation, physiology and dynamics
3_6	Organelle biology
3_7	Cell signalling and cellular interactions Signal transduction
3_8	
3_9	Development, developmental genetics, pattern formation and embryology Cell genetics
3_10 3_11	Stem cell biology
3_12	Morphology and functional imaging of cells
4	Physiology, Pathophysiology and Endocrinology
4_1	Organ physiology and pathophysiology
4_3	Endocrinology
4_4	Ageing
4_5	Metabolism, biological basis of metabolism related disorders
4_6	Cancer and its biological basis
4_7	Cardiovascular diseases
4_8	Non-communicable diseases (except for neural/psychiatric, immunity-related, metabolism-
	related disorders, cancer and cardiovascular diseases)
5	Neurosciences and Neural Disorders
5_1	Neuroanatomy and neurophysiology
5_2	Molecular and cellular neuroscience
5_3	Neurochemistry and neuropharmacology
5_4	Sensory systems (e.g. visual system, auditory system)
5_5	Mechanisms of pain
5_6	Developmental neurobiology
5_7	Cognition (e.g. learning, memory, emotions, speech)
5_8	Behavioural neuroscience (e.g. sleep, consciousness, handedness)
5_9	Systems neuroscience
5_10	Neuroimaging and computational neuroscience
5_11	Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's
	disease)
5_12	Psychiatric disorders (e.g. schizophrenia, autism, Tourette's syndrome, obsessive compulsive disorder, depression, bipolar disorder, attention deficit hyperactivity disorder)
6	Immunity and Infection
6_1	Innate immunity and inflammation
6_2	Adaptive immunity
6_3	Phagocytosis and cellular immunity
6_4	Immunosignalling
6_5	Immunological memory and tolerance
6_6	Immunogenetics
6_7	Microbiology
6_8	Virology
6_9	Bacteriology
6_10	Parasitology
6_11	Prevention and treatment of infection by pathogens (e.g. vaccination, antibiotics, fungicide)
6_12	Biological basis of immunity related disorders (e.g. autoimmunity)

In collaboration with:

With the support of:

fctt Fundação para a Ciência e a Tecnologia





7	Diagnostic Tools, Therapies and Public Health
7_1	Medical engineering and technology
7_2	Diagnostic tools (e.g. genetic, imaging)
7_3	Pharmacology, pharmacogenomics, drug discovery and design, drug therapy
7_4	Analgesia and Surgery
7_5	Toxicology
7_6	Gene therapy, cell therapy, regenerative medicine
7_7	Radiation therapy
7_8	Health services, health care research
7_9	Public health and epidemiology
7_10	Environment and health risks, occupational medicine.
8	Applied life Sciences and Non-Medical Biotechnology
8_1	Applied genetic engineering, transgenic organisms, recombinant proteins, biosensors
82	Synthetic biology, chemical biology and new bio-engineering concepts

**8\_3** Food sciences

## Classify your proposal, mandatory.

Individual proposal
Consortium

## Classify your proposal, mandatory.

Proposal without Co-Owner(s) of Asset/s
Proposal with Co-Owner(s) of Asset/s

If user selects Proposal with Co-Owner(s) of Asset/s, then "Co-Owner of Asset/s details" is shown.

## **INFORMATION FOR "LA CAIXA"**

This information will be only used for monitoring/statistical purposes.

Are you or any member of your group applying to any other "la Caixa" Foundation call (research, innovation projects and fellowships), **mandatory**.

Yes
No

## *If user answers yes to the previous question:*

Please indicate the application code (such as HR20-00001, Cl19-00001...) for each of the proposals where you or a member of your group apply:

#	Application code
1	HR21-00001
2	CI21-00001
3	CC21-10001

Criteria Bio Ventures

\chi Caixa Capital Risc





Have you or any members of your group been selected in a previous call of the "la Caixa" Foundation (research, innovation projects and fellowships)? Please include all ongoing or finished projects. **Mandatory**.

Yes
No

## If user answers yes to the previous question:

Please indicate the application code (such as HR20-00001, Cl18-00001, CC21-00002...)) for each of the proposals where you or a member of your group took part.

#	Application code
1	HR20-00001


## Select the option that best suits your proposal, mandatory.

Cardiovascular
Experimental and mathematical sciences
Infectious diseases
Medical sciences
Neurosciences
Oncology
Other health sciences

In collaboration with:

Criteria*Bio*Ventures X Caixa Capital Risc





## PLEASE CHOOSE THE SCENARIO THAT BETTER MATCHES THE CURRENT STATUS OF YOUR PROJECT.

## SCENARIO 1:

- 1. A Proof of Concept experiment has not been carried out yet.
- 2. The Intellectual Property strategy is still not defined or it is unclear.
- 3. The team expertise is mainly scientific.
- 4. The requested funding will be mainly used for *proving that your idea* may be a good solution for the need it intends to address.
- 5. According to the Technology Readiness Levels (TRL), your project will be marked as TRL 1-2.

## **SCENARIO 2:**

- **1.** Initial *Proof of Concept* experiments that led to the definition of the Asset/s have been carried out.
- **2.** The Intellectual Property strategy of the Asset/s is defined.
- 3. The value proposition for the Asset/s is defined.
- 4. The team expertise is mainly scientific, but some tech transfer profiles may be incorporated.
- 5. The requested funding will be used to advance on the scientific and/or technical development of the Asset/s, but activities focused on legal, business, and commercial aspects may also be performed.
- 6. The team has identified who the clients and end-users of the Asset/s are, and envision how the Asset/s will generate revenues.
- 7. According to the Technology Readiness Levels (TRL), your project will be marked as TRL 3-4.

## **SCENARIO 3:**

- **1. The team has carried out a relevant** *Proof of Concept* **of the Asset/s in** *relevant models* **or test environments.**
- 2. The Intellectual Property strategy is defined and it is being implemented.
- **3.** There are some tech transfer profiles engaged in the project.
- 4. The value proposition of the Asset/s is defined.
- **5. The requested funding will be used to advance on the scientific and/or technical development of the Asset/s, but** *activities focused on legal, business, and commercial aspects* **will be performed as well.**
- 6. The team has procured partnerships with prospective licensees and/or private investors.
- 7. The team has a plan to meet the *regulatory requirements* the Asset/s should abide by.
- 8. The team has *identified risks* ahead on the route towards the market and have a plan to overcome them.
- **9.** The team has identified who the *clients and end-users of the Asset/s* are, and envision how the Asset/s will generate revenues.
- **10. The team has performed a deep** analysis on the market and competitors.
- **11.** The *exploitation plan* for the Asset/s is outlined.
- **12.** According to the Technology Readiness Levels (TRL), your project will be marked as *TRL 4* or higher.


Scenario 1 / Scenario 2 / Scenario 3. Mandatory

#### In collaboration with:

Criteria*Bio*Ventures







## **PROPOSAL ABSTRACT**

The abstract must provide a brief description of the project, the specific objectives and the values that it brings to its scientific field and society. **2000 characters. Mandatory.** 

## LAY SUMMARY

Briefly summarize the project, including a description of the Asset, for a non-expert audience. **1000 characters. Mandatory.** 

# Stage 1

Block 1 – Asset

## BRIEF DESCRIPTION OF YOUR ASSET/S

Describe your Asset/s. 500 Characters. Mandatory.

## SCIENTIFIC RATIONALE

» Explain the scientific excellence and originality of the Asset/s in the context of the state-ofthe-art. **1000 characters. Mandatory.** 

## FIVE MOST IMPORTANT SCIENTIFIC PUBLICATIONS

» Up to 5 references. Optional.

#	DOI	Title of the document	Authors	Journal	Year

## SUPPORTING DATA

» Describe the preliminary data that supports the hypothesis and the scientific approach of your idea. **2000 characters. Mandatory**.

SCIENTIFIC FIGURES SUPPORTING YOUR ASSET/S'

» Only one PDF of maximum 3 Pages. Mandatory.

## Block 2 – Need


## NEED OR PROBLEM TO BE SOLVED

Description of the unmet clinical needs you envision the Asset/s may cover. **2500 characters. Mandatory.** 

In collaboration with:

Criteria*Bio*Ventures





## Block 3 – Team

## PROJECT LEADER'S EXPERIENCE AND EXPERTISE

Describe the capabilities of the project leader that would contribute to the development of the Asset/s. Describe the future involvement in the project beyond this program. **1500 characters. Mandatory.** 

## TEAM MEMBERS TABLE

Initials full name	Job title, centre	Email	Profile, experience	Dedication
6 characters.	100 characters	100 characters.	1000 characters.	1000 characters

## COMPLEMENTARITY OF THE TEAM MEMBERS

» Provide details of the team members' profile, previous experience, and dedication and commitment to the project. Describe how they are relevant and complementary for its successful execution. **1500 characters. Mandatory.** 

## LETTERS OF SUPPORT OR RECOMMENDATION

» One PDF up to 5 MB. Optional

## Block 4 – Implementation

## **PROJECT MILESTONES**

Describe the specific milestones for the next two years. 1000 characters. Mandatory

## ACTIVITIES TO BE PERFORMED

» Please describe all activities estimated to be developed for the next two years and indicative cost according to table provided under "Budget" section. All the actions should be linked to specific project milestones.

2500 characters. Mandatory.

BUDGET

See Annex I

## Block 5 – Business Case and social impact


## TRANSFORMATION EXPECTATIONS FOR SOCIETY

» Describe the potential contribution of the Asset/s in improving people's quality of life, social progress, and human development. **2000 characters. Mandatory.** 

In collaboration with:

Criteria*Bio*Ventures <u>X Caixa Capital Risc</u>





Stage 2

## Block 1 – Asset

## BRIEF DESCRIPTION OF YOUR ASSET/S. Describe your Asset/s. **500 Characters. Mandatory.**

## SCIENTIFIC RATIONALE

» Explain the scientific excellence and originality of the Asset/s in the context of the state-ofthe-art. **1000 characters. Mandatory.** 

## FIVE MOST IMPORTANT SCIENTIFIC PUBLICATIONS

» Up to 5 references. Optional.

#	DOI	Title of the document	Authors	Journal	Year

## SUPPORTING DATA

» Describe the preliminary data that supports the hypothesis and the scientific approach of your idea. **2000 characters. Mandatory.** 

SCIENTIFIC FIGURES SUPPORTING YOUR ASSET/S'

» Only one PDF of maximum 3 Pages. Mandatory.

DO YOU HAVE AN INTELLECTUAL PROPERTY RIGHTS STRATEGY IN PLACE? (THIS MEANS ANY FILED PATENT OR UTILITY MODEL, TRADEMARK, INDUSTRIAL DESIGN RIGHT OR TRADE SECRET).

## » Yes/No. Mandatory

## *If user answers yes to the previous yes/no question:*

WHICH IPR STATUS MATCHES BETTER YOUR ASSET/S

## » Please indicate the Protection status of the Asset/s. Mandatory


Patent pending
Utility model pending
Patent granted
Utility model granted
Trademark
Industrial design right
Trade Secret
Copyright

In collaboration with:

Criteria*Bio*Ventures <u>X</u> Caixa Capital Risc







## BRIEFLY DESCRIBE WHAT EXACTLY IS PROTECTED.

» Which is claimed in your patent/utility model/industrial design/trademark or protected by trade secret? Please also add the regions and time scope in which your Asset/s is protected. Please, also provide any other information that may support your IPR position (e.g., ISR, EESR, or Freedom to Operate Analysis). Also, please, add information about any future actions about IPR in the future. **2000 characters. Mandatory.** 

## RELEVANT PATENT OR UTILITY MODEL DOCUMENTS.

» One PDF up to 5 MB. Optional

## If user answers no to the previous yes/no question:

## WHAT IP PROTECTION STRATEGY DO YOU PLAN TO FOLLOW? PLEASE PROVIDE ANY INFORMATION SUPPORTING IT.

» How do you plan to protect your Asset/s to support its exploitation? Why do you think this would be the best option to protect your Asset/s? **Mandatory, 1500 characters.** 

## Block 2 – Need

## NEED OR PROBLEM TO BE SOLVED

» Description of the reasons behind the development of the Asset/s. Describe the unmet need or problem it addresses and the foreseen impact after its implementation. **2500 characters. Mandatory.** 

## POTENTIAL OF YOUR ASSET/S TO BE USED FOR OTHER UNMET NEEDS

» Briefly describe other possible indications you envision your idea may be used for. **1000 characters. Mandatory.** 

## VALUE PROPOSITION

» Describe whether the product represents a novelty compared to the current solutions. **2000 characters. Mandatory.** 

## IDENTIFICATION AND INVOLVEMENT OF THE DIFFERENT STAKEHOLDERS

» Which people or groups of people are critical for the success of the project and could therefore have a positive or negative effect on the transfer to the market? (patient as., clients, endusers, beneficiaries, prescriptors, etc...) **2000 characters. Mandatory.** 

## Block 3 – Team

## PROJECT LEADER'S EXPERIENCE AND EXPERTISE


 » Describe the capabilities of the project leader that would contribute to the development of the Asset/s. Describe the future involvement in the project beyond this program.
1500 characters. Mandatory.

In collaboration with:

Criteria Bio Ventures

💥 Caixa Capital Risc





## PROJECT LEADER'S AND TEAM'S EXPERIENCE IN TECH TRANSFER AND INNOVATION.

» Describe the project leader's and team member's level of knowledge in the fields of business management, technology transfer, and innovation management. 1500 characters. Mandatory.

#### TEAM MEMBERS TABLE

Initials full name	Job title, centre	Email	Profile, experience	Dedication
6 characters.	100 characters	100 characters.	1000 characters.	1000 characters

## COMPLEMENTARITY OF THE TEAM MEMBERS

» Provide details of the team members' profile, previous experience, and dedication and commitment to the project. Describe how they are relevant and complementary for its successful execution. **1500 characters. Mandatory.** 

#### LETTERS OF SUPPORT OR RECOMMENDATION

» One PDF up to 5 MB. Optional

## **Block 4- Implementation**

## PROJECT MILESTONES

» Describe the specific milestones for the next two years. Please explain how these objectives relate to the complete Roadmap of Asset/s development until commercialisation. **1000** characters. Mandatory.

## ACTIVITIES TO BE PERFORMED

» Please, describe all activities to be developed for the next two years and indicative cost according to table provided under "Budget" section. All the actions should be linked to specific project milestones. **2500 characters. Mandatory.** 

## WORK PLAN (GANTT CHART)

- » Please indicate the proposal workplan in a Gantt Diagram. Use the + button below to add Tasks. They will be displayed in the Gantt Chart below, after doing save draft.
- » To enter each Gantt task, the user should enter a Task Name, a Start Date, an End Date and a Description of no more than 500 characters. **Mandatory**.

## OTHER SUPPORT

» Description of support (financial/non-financial) received from other collaborations/programs to implement actions in the Development Roadmap. Discuss prospective support or collaborations that you have already procured. **1000 characters. Mandatory.** 


BUDGET

» See Annex I

In collaboration with:

Criteria*Bio*Ventures X Caixa Capital Risc





## Block 5 – Business case and social impact

## TRANSFORMATION EXPECTATIONS FOR SOCIETY

» Describe the potential contribution of the Asset/s in improving people's quality of life, social progress, and human development. **2000 characters. Mandatory.** 

## HOW DO YOU ENVISION THAT YOUR ASSET/S WOULD BE ATTRACTIVE FOR THE MARKET?

» How do you envision that your Asset/s will produce revenues and be sustainable in the long term? Who will pay for it (client)? **2000 characters. Mandatory.** 

# Stage 3

## Block 1 – Asset

BRIEF DESCRIPTION OF YOUR ASSET/S.

» Describe your Asset/s. 500 Characters. Mandatory.

## SCIENTIFIC RATIONALE

» Explain the scientific excellence and originality of the Asset/s in the context of the state-ofthe-art. **1000 characters. Mandatory.** 

## FIVE MOST IMPORTANT SCIENTIFIC PUBLICATIONS

» Up to 5 references. Optional.

#	DOI	Title of the document	Authors	Journal	Year

## SUPPORTING DATA

» Describe the preliminary data that supports the hypothesis and the scientific approach of your idea. **Mandatory. 2000 characters.** 

SCIENTIFIC FIGURES SUPPORTING YOUR ASSET/S' » Only one PDF of maximum 3 Pages. **Optional.** 

DO YOU HAVE AN INTELLECTUAL PROPERTY RIGHTS STRATEGY IN PLACE? (THIS MEANS ANY FILED PATENT OR UTILITY MODEL, TRADEMARK, INDUSTRIAL DESIGN RIGHT OR TRADE SECRET). » Yes/No. Mandatory


If the user answers yes to the previous yes/no question: WHICH IPR STATUS MATCHES BETTER YOUR ASSET/S » Please indicate the Protection status of the Asset/s. Mandatory

In collaboration with:

Criteria Bio Ventures

💥 Caixa Capital Risc





Patent pending
Utility model pending
Patent granted
Utility model granted
Trademark
Industrial design right
Trade Secret
Copyright

## BRIEFLY DESCRIBE WHAT EXACTLY IS PROTECTED.

» Which is claimed in your patent/utility model/industrial design/trademark or protected by trade secret? Please, also add the regions and time scope in which your Asset/s is protected. Please, also provide any other information that may support your IPR position (e.g., ISR, EESR, or Freedom to Operate Analysis). Also, please, add information about any future actions about IPR in the future. **Mandatory. 2000 characters.** 

## RELEVANT PATENT OR UTILITY MODEL DOCUMENTS.

» One PDF up to 5 MB. Optional

## If user answers no to the previous yes/no question:

WHAT IP PROTECTION STRATEGY DO YOU PLAN TO FOLLOW? PLEASE PROVIDE ANY INFORMATION SUPPORTING IT.

» How do you plan to protect your Asset/s to support its exploitation? Why do you think this would be the best option to protect your Asset/s? **Mandatory. 1500 characters.** 

## Block 2 – Need

## NEED OR PROBLEM TO BE SOLVED

» Description of the reasons behind the development of the Asset/s. Describe the unmet need or problem it addresses and the foreseen impact after its implementation. **2500 characters. Mandatory.** 

## POTENTIAL OF YOUR ASSET/S TO BE USED FOR OTHER UNMET NEEDS

» Briefly describe other possible indications you envision your idea may be used for. **1000** characters. Mandatory.

## VALUE PROPOSITION

» Describe whether the product represents a novelty compared to the current solutions. **2000 characters. Mandatory.** 


## IDENTIFICATION AND INVOLVEMENT OF THE DIFFERENT STAKEHOLDERS

» Which people or groups of people are critical for the success of the project and could therefore have a positive or negative effect on the transfer to the market? (patient associations, clients, end-users, beneficiaries, prescriptors, etc...) **2000 characters. Mandatory.** 

Criteria Bio Ventures

💥 Caixa Capital Risc





## Block 3- Team

## PROJECT LEADER'S EXPERIENCE AND EXPERTISE

 » Describe the capabilities of the project leader that would contribute to the development of the Asset/s. Describe the future involvement in the project beyond this program. 1500 characters. Mandatory.

## PROJECT LEADER'S AND TEAM'S EXPERIENCE IN TECH TRANSFER AND INNOVATION

 » Describe the project leader's and team members' level of knowledge in the fields of business management, technology transfer, and innovation management.
1500 characters. Mandatory.

## TEAM MEMBERS TABLE

itle, centre Email	Profile,	experience Ded	ication
haracters 100 c	haracters. 1000 ch	aracters. 100	0 characters
	,	·····	ź

#### COMPLEMENTARITY OF THE TEAM MEMBERS

» Provide details of the team members' profile, previous experience, and dedication and commitment to the project. Describe how they are relevant and complementary for its successful execution. **1500 characters. Mandatory.** 

## SKILLS GAP ANALYSIS

» Identify the skills envisaged to be acquired in order to advance the project and how you plan to attract them (e.g., recruiting, training team members, outsourcing). **1500 characters. Mandatory.** 

## Block 4 – Implementation

## PROJECT MILESTONES

» Describe the specific milestones for the next two years. Please explain how these objectives relate to the complete Roadmap of Asset/s development until commercialisation. **1000** characters. Mandatory.

## ACTIVITIES TO BE PERFORMED

» Please describe all activities to be developed for the next two years and indicative cost according to table provided under "Budget" section. All the actions should be linked to specific project milestones. **2500 characters. Mandatory.** 

## WORK PLAN (GANTT CHART)


- » Please indicate the proposal workplan in a Gantt Diagram. Use the + button below to add Tasks. They will be displayed in the Gantt Chart below, after doing save draft.
- » To enter each Gantt task, the user should enter a Task Name, a Start Date, an End Date and a Description of no more than 500 characters. **Mandatory.**

In collaboration with:

Criteria Bio Ventures

💥 Caixa Capital Risc





## RISK ANALYSIS

» Please describe the type of risk your project will face (technological, commercial, financial, etc...), explain how likely these risks will appear and how you plan to overcome them. **1500** characters. Mandatory.

## OTHER SUPPORT

» Description of the support (financial/non-financial) received from other collaborations/programs to implement actions in the Development Roadmap. Discuss prospective support or collaborations that you have already procured. **1000 characters. Mandatory.** 

## NON-FINANCIAL SUPPORT NEEDED

» Detail the specific non-financial support that is foreseen in this stage of the project. **1000** characters. Mandatory.

#### REGULATORY ROADMAP

» Explain the regulatory requirements to be fulfilled for the exploitation of the Asset/s and how they are to be met. **1500 characters. Mandatory.** 

BUDGET

» See Annex I

## Block 5 – Business case and social impact

## TRANSFORMATION EXPECTATIONS FOR SOCIETY

» Describe the potential contribution of the Asset/s in improving people's quality of life, social progress, and human development. **2000 characters. Mandatory.** 

HOW DO YOU ENVISION THAT YOUR ASSET/S WOULD BE ATTRACTIVE FOR THE MARKET?

» How do you envision that your Asset/s will produce revenues and be sustainable in the long term? Who will pay for it (client)? **2000 characters. Mandatory.** 

## EXPLOITATION STRATEGY

» Describe your exploitation plan as well as the key steps to reach the market. Indicate possible collaborations with third parties for making a successful commercial exploitation. Explain the main market barriers and how you plan to overcome them. You can add a full business plan as an attachment (optional). **2000 characters. Mandatory.** 

## MARKET ANALYSIS AND COMPETITORS

» Indicate the most relevant market segments to reach and possible collaboration with third parties for making a successful commercial exploitation. Analyze the competing approaches in the field. Estimation of the potential market size. **2000 characters. Mandatory.** 

TWO-PAGER BUSINESS DECK OR BUSINESS PLAN


» One PDF up to 5MB. Optional

In collaboration with:

Criteria Bio Ventures

💥 Caixa Capital Risc





## Annex I. Budget Table

	Amount Requested by the beneficiary	Amount requested by partner (1,,4) *	Other Contributions	Comments**
Total				
Materials for experiments / R&D				
Outsourcing of activities for R&D development				
Personnel for the project				
Intellectual property protection				
Technical/scientific advice				
Business advice				
Legal advice				
Market analysis				
Regulatory development				
Production and Quality				
Design				
Prototyping				
Travel expenses related to the project				
Others				
Overheads***				
Commercial and Business Development actions				

## NOTES:

\*One column (up to 4) will appear per invited partner (if any).

\*\*Comments are compulsory for every line in which money is allocated, with a maximum of 500 characters per line

\*\*\*Overheads are only eligible up to a 10% of the total budget in Stage 2 and Stage 3 applications.

Maximum budget is €50,000 for Stage 1, €150,000 for Stage 2, and €500,000 for Stage 3.

In collaboration with:

With the support of:

Criteria*Bio*Ventures

